Parity of EGFR and c-ErbB-2 Overexpressions in Hepatocellular Carcinoma: An Immunohistochemical Study
문우성, 박호성, 손현진, 박민영,
소속 상세정보
문우성 ( Moon Woo-Sung )
전북대학교 의과대학 병리학교실
박호성 ( Park Ho-Sung )
전북대학교 의과대학 병리학교실
손현진 ( Son Hyun-Jin )
전북대학교 의과대학 병리학교실
박민영 ( Park Min-Young )
전북대학교 의과대학 병리학교실
KMID : 0357920040380040244
Abstract
Background: The overexpression of epidermal growth factor receptor (EGFR) and c-erbB-2 oncogenes has been implicated in the development of many types of cancer. However, the role of EGFR and c-erbB-2 overexpression in hepatocellular carcinoma (HCC) has not been fully elucidated.
Methods: The aim of this study was to evaluate the immunohistochemical expression of EGFR and c-erbB-2 oncoprotein in a series of 52 HCCs.
Results: All but one of the HCC tumor tissues were negative for EGFR monoclonal antibody, clone H11. All of the HCC tumor tissue samples were negative for EGFR monoclonal antibody, clone 29.1.1. However, strong EGFR immunoreactivity was detected in sinusoidal endothelial cells of HCC in 25 tumors (48%) using EGFR 29.1.1 antibody. The expression of c-erbB-2 was observed in 6% (3/52) of the HCCs. No significant correlation was found between p53 mutation and the expression of c-erbB-2.
Conclusion: Our results suggest that both EGFR and c-erbB-2 oncoprotein overexpressions in tumor cells are rare and do not seem to predominantly contribute to the malignant phenotype in HCC.
키워드
Carcinoma;Hepatocellular;Receptor;Epidermal Growth Factor-erbB2;Immunohistochemistry
원문 및 링크아웃 정보
등재저널 정보